RecruitingPhase 2NCT05737121

Safety and Efficacy Study of VNX001 Compared to Its Individual Components (Lidocaine and Heparin) or Placebo in Subjects With IC/BPS

Studying Interstitial cystitis

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Vaneltix Pharma, Inc.
Intervention
VNX001(drug)
Enrollment
120 target
Eligibility
18 years · All sexes
Timeline
20232026

Study locations (14)

Collaborators

Prevail Infoworks

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT05737121 on ClinicalTrials.gov

Other trials for Interstitial cystitis

Additional recruiting or active studies for the same condition.

See all trials for Interstitial cystitis

← Back to all trials